Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Withdrawn 2Completed 2

Sponsor Class

INDUSTRY 13OTHER 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Genitourinary 1

Conditions

Solid Tumors 1Neoplasms 1Lung Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Interventional × vadimezan × Clear all
NCT01071928 2015-08-19

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

NCT01031212 2013-05-13

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

University of California, San Francisco

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT01057342 2013-04-10

Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Swiss Cancer Institute

Phase 2 Completed
17 enrolled
Thoracic

Lung Neoplasms

NCT00863733 2009-03-18

DMXAA

Cancer Research UK

Phase 1 Completed
63 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡